Navigation Links
Two common diabetes drugs double the risk of fractures in women
Date:12/9/2008

Two common diabetes drugs rosiglitazone and pioglitazone are linked to higher fracture rates in women, according to a meta-analysis in CMAJ by a team of researchers from the University of East Anglia in the United Kingdom and Wake Forest University in the United States http://www.cmaj.ca/press/080486.pdf.

The drugs, called thiazolidinediones, help improve glycemic control and decrease insulin resistance in patients with diabetes.

The researchers looked at 10 randomized controlled trials of at least one year's duration involving 13 715 diabetes patients taking thiazolidinediones and those not taking the therapy. They found significantly reduced bone density in the lumbar spine and at the hip in women on the drugs.

It appears that long-term thiazolidinedione use doubles the risk of fractures among women with type 2 diabetes, without a significant increase in fracture risk in men. The researchers estimate that a fracture would occur in 1 out of 21 women at high risk of fracture who are taking thiazolidinedione for one year and among low risk women, there would be 1 fracture in every 55 if these drugs are taken for more than a year.

With more than 4 million users of thiazolidinediones in the United States alone in 2006, "the public health impact may be considerable," write Dr. Yoon Loke and coauthors. "If one assumes that half of those users were women and that the baseline risk of fractures is similar to that found in the ADOPT study, an estimated 30 000 excess fractures may have occurred if these women had been prescribed thiazolidinediones rather than metformin for more than a year."

The researchers call for further investigation into the underlying causes of this apparent sex-specific effect.

In a related commentary http://www.cmaj.ca/press/081713.pdf, Dr. Lorraine Lipscombe of the Institute for Clinical Evaluative Sciences and the University of Toronto writes that "clinical drug trials are often underpowered to detect unanticipated and rare adverse effects, and a standardized postmarketing surveillance process is needed." She cautions that the net benefit of these drugs is unclear, and there are other effective drugs that can control glycemia with fewer adverse events.


'/>"/>

Contact: Kim Barnhardt
kim.barnhardt@cma.ca
613-731-8610 x2224
Canadian Medical Association Journal
Source:Eurekalert

Related medicine news :

1. UK junior doctors gaining less experience of common procedures
2. New insights into common knee injuries
3. High and mighty: first common height gene identified by researchers behind obesity gene finding
4. Figure Skater Peggy Fleming, HealthSaver Says: Take Pains For Back Strains, 2nd Most Common Doctor Complaint
5. Exelixis Commences Public Offering of Common Stock
6. Common misdiagnosis: most women believe they have a yeast infection when they dont
7. Business Executives Discuss National Health Care Reform at Conference Sponsored by The Century Foundation, with Support from The Commonwealth Fund, and AARP
8. New Expert Report Dispels Common Myths About Aspartame
9. Common Foot Myths Trip Us Up
10. AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange
11. Allergy-Induced Asthma More Common in Affluent Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 02, 2016 , ... ... the Open Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare ... plan (Part C) or prescription drug plan (Part D) need to make changes during ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... inspirational interview of two ostomy patients, standing as living proof that attitude and ... from digestive diseases and issues that spike around the holidays. This campaign will ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic technologies, ... while maintaining fulfilling lives. “We are prolonging life 6 years in the last ...
(Date:12/2/2016)... OH (PRWEB) , ... December 02, 2016 , ... ... of veterinarian diagnostic imaging systems and the first company to offer ... With a Heart at their tradeshow booth # 941 for the American Association ...
(Date:12/2/2016)... ... 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, ... into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in ... the details line up exactly with Bible Prophecy – a protected way for those ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 1, 2016  Today, Simpson Healthcare Executives, ... honor of being selected as winners of multiple awards ... Executives Website at the PLATINUM level, Blue Zones Menu ... at the GOLD Level, and our proprietary 3ConneX Platform ... Simpson Healthcare Executives, we are excited to showcase our ...
(Date:12/2/2016)... BRUSSELS , Dec. 2, 2016  UCB is pleased to ... presentation at the upcoming 70 th American Epilepsy Society ... Houston, TX , USA. 1-12 ... safety and efficacy profile of VIMPAT ® (lacosamide) CV ... also share findings on the current state of the union ...
(Date:12/2/2016)... Dec. 2, 2016 Allergan plc (NYSE: ... information on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a ... the Company will repurchase $10 billion of its ordinary shares. ...
Breaking Medicine Technology: